Clinical Trials

Urinary Bladder Neoplasms

NCT02516241 2026-04-20

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

1,126 enrolled 52 charts

Urothelial Cancer

NCT05911295 2026-04-20

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

412 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06545955 2026-04-20

ABLE-22

250 enrolled

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

NCT03967977 2026-04-17

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

420 enrolled

Carcinoma, Transitional Cell

NCT03661320 2026-04-15

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

855 enrolled

Urinary Bladder Neoplasms

NCT07106762 2026-04-15

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

Phase 2/3 Recruiting

470 enrolled

Urinary Bladder Neoplasms

NCT04658862 2026-04-13

SunRISe-2

518 enrolled

Urinary Bladder Neoplasms

NCT06211764 2026-04-13

SunRISe-5

272 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06319820 2026-04-13

MoonRISe-1

641 enrolled

Phase 2 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

350 enrolled

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT06960577 2026-03-30

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

150 enrolled

Urinary Bladder Neoplasms

NCT03288545 2026-03-24

EV-103

Phase 1/2 Terminated

348 enrolled 2 FDA

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT07129993 2026-03-19

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Phase 2/3 Recruiting

630 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03547973 2026-03-16

TROPHY U-01

Phase 2 Recruiting

827 enrolled 2 FDA

Metastatic Urothelial Cancer

NCT03732677 2026-03-13

NIAGARA

1,063 enrolled 15 charts 2 FDA

Urinary Bladder Neoplasms

NCT06919965 2026-03-13

MoonRISe-3

220 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT03036098 2026-03-06

CheckMate901

1,314 enrolled 23 charts 2 FDA

Urothelial Cancer

NCT07393542 2026-03-03

A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma

462 enrolled

Carcinoma, Transitional Cell

NCT04172675 2026-02-24

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Phase 2 Completed

107 enrolled 17 charts

Phase 3 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07424287 2026-02-20

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

236 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT04700124 2026-02-05

KEYNOTE-B15

Phase 3 Completed

808 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT03682068 2026-02-03

NILE

1,246 enrolled

Phase 1 Active not recruiting

Urinary Bladder Neoplasms

NCT05867121 2026-02-02

A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

102 enrolled

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Stomach Neoplasms

NCT03869190 2026-01-22

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Phase 1/2 Completed

272 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05375903 2026-01-14

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

51 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04003610 2025-11-04

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Phase 2 Terminated

7 enrolled 10 charts

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Acrocephalosyndactylia, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Phase 1/2 Terminated

137 enrolled 31 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT06829823 2025-10-16

Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer

Phase 2 Not yet recruiting

20 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT04887831 2025-09-08

PRESERVE3

Phase 2 Terminated

92 enrolled 24 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03924856 2025-08-28

KEYNOTE-866

907 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

613 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT06632951 2025-08-11

LIVIGNO-3

Phase 2 Active not recruiting

150 enrolled

Phase 1 Active not recruiting

Carcinoma, Transitional Cell, Neoplasms

NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

138 enrolled

DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT04306900 2025-07-29

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

GastrointestinalGenitourinaryThoracic

185 enrolled 28 charts

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03884556 2025-07-02

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

GastrointestinalGenitourinaryLymphoidThoracic

56 enrolled 19 charts

Urinary Bladder Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms

NCT04223856 2025-06-13

EV-302

886 enrolled 12 charts 2 FDA

Urothelial Cancer

NCT06663137 2025-06-13

HGNMIBC

Phase 2 Recruiting

70 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Non-Muscle Invasive Bladder Neoplasms

NCT04068896 2025-05-29

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

Phase 1/2 Completed

89 enrolled 21 charts

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT06493552 2025-04-03

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

Phase 2/3 Recruiting

700 enrolled

Carcinoma, Transitional Cell

NCT02807636 2025-02-24

IMvigor130

Phase 3 Completed

1,213 enrolled 35 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04241185 2024-11-25

MK-3475-992

520 enrolled

Urinary Bladder Neoplasms

NCT02009449 2024-11-15

IVY

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

353 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT06592326 2024-09-19

9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer

460 enrolled

Carcinoma, Transitional Cell

NCT01625260 2024-07-19

A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer

Phase 1/2 Terminated

12 enrolled 13 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Recurrence

NCT01326871 2024-06-25

A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

Phase 1/2 Completed

68 enrolled 13 charts

Urinary Bladder Neoplasms, Neoplasm Metastasis, Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT05302284 2023-12-18

A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

452 enrolled

Carcinoma, Transitional Cell

NCT05943379 2023-07-13

RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects

Phase 2 Recruiting

85 enrolled